Literature DB >> 22688069

Diagnostic imaging of higher brain dysfunction in patients with adult moyamoya disease using statistical imaging analysis for [123I]iomazenil single photon emission computed tomography.

Jyoji Nakagawara1, Toshiaki Osato, Kenji Kamiyama, Kaori Honjo, Hironori Sugio, Kentarou Fumoto, Takeo Murahashi, Hidekazu Takada, Toshiichi Watanabe, Hirohiko Nakamura.   

Abstract

[123I]iomazenil (IMZ) is a specific radioligand for the central benzodiazepine (BZ) receptor that may be useful as a marker of cortical neuron loss after cerebral ischemia using single photon emission computed tomography (SPECT). This study used statistical imaging analysis for IMZ-SPECT to investigate the relationship between higher brain dysfunction and cortical neuron loss in the medial frontal lobes, to establish a confirmatory diagnosis of higher brain dysfunction in patients with adult moyamoya disease. IMZ-SPECT was estimated by three-dimensional stereotactic surface projections (3D-SSP). Cortical neuron loss was analyzed using the stereotactic extraction estimation (SEE) method (level 3: gyrus level) for 3D-SSP Z-score maps (Z-score >2). Extent of pixels with significant reduction of BZ receptor density within the target gyri (i.e. bilateral medial frontal gyri [MFGs] and anterior cingulate gyri [ACGs]) was calculated. In 6 patients with higher brain dysfunction, significant cortical neuron loss was observed in the bilateral MFGs in 4 patients, unilateral MFG in 1 patient, and bilateral ACGs in 2 patients. In 12 patients without higher brain dysfunction, no significant cortical neuron loss was observed in the bilateral MFGs or ACGs, and mild loss was observed in the bilateral MFGs in 2 patients, unilateral MFG in 4 patients, and unilateral ACG in 2 patients. Long-standing mild hemodynamic ischemia in the anterior circulation of patients with adult moyamoya disease could lead to incomplete brain infarction within the medial frontal lobes. Statistical imaging analysis using 3D-SSP and SEE methods for IMZ-SPECT could demonstrate significant cortical neuron loss in the bilateral frontal medial cortices involving MFG and/or ACG which correlate with higher brain dysfunction in patients with adult moyamoya disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688069     DOI: 10.2176/nmc.52.318

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  5 in total

Review 1.  Cognitive Dysfunction Survey of the Japanese Patients with Moyamoya Disease (COSMO-JAPAN Study): study protocol.

Authors:  Yasushi Takagi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2015-02-20       Impact factor: 1.742

2.  Transient Symptomatic Downregulation of Cortical Neurotransmitter Receptor Function Due to Cerebral Hyperperfusion after Arterial Bypass Surgery for a Patient with Ischemic Moyamoya Disease.

Authors:  Yasuyoshi Shimada; Daigo Kojima; Jun Yoshida; Masakazu Kobayashi; Kenji Yoshida; Shunrou Fujiwara; Kuniaki Ogasawara
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-10-25       Impact factor: 1.742

Review 3.  Late Cerebrovascular Events and Social Outcome after Adolescence: Long-term Outcome of Pediatric Moyamoya Disease.

Authors:  Takeshi Funaki; Jun C Takahashi; Susumu Miyamoto
Journal:  Neurol Med Chir (Tokyo)       Date:  2018-05-21       Impact factor: 1.742

4.  Evaluation of 99mTC-ECD SPECT/CT brain Imaging with NeuroGam analysis in Moyamoya disease after surgical revascularization.

Authors:  Jingjing Lou; Zhuang Liu; Bin Xu; Yuan-Kai Wang; Cong-Jin Liu; Miao Liu; Xing-Dang Liu
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  Characterizing the neurocognitive profiles of children with moyamoya disease using the Das Naglieri cognitive assessment system.

Authors:  Yusuke Kusano; Takeshi Funaki; Keita Ueda; Noyuri Nishida; Kanade Tanaka; Susumu Miyamoto; Shuichi Matsuda
Journal:  Sci Rep       Date:  2022-03-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.